WHO anticipates effective Ebola vaccine
Helman Laboratories in Singapore have developed a vaccine candidate against the rare Bundibugyo strain of the Ebola virus, for which there is currently no approved treatment or vaccine. The World Health Organization considers this vaccine the most promising candidate to combat the ongoing outbreak in the Democratic Republic of Congo, and the laboratories are preparing to initiate clinical trials soon. The new vaccine is notable for its ability to be stored for months at normal temperatures, facilitating distribution in remote areas and reducing costs compared to the Irvipo vaccine, which requires very cold storage.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)